Meeting
2022 ASCO Annual Meeting
Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.
Authors
Shaji Kumar
Mayo Clinic, Rochester, MN
Shaji Kumar , Giada Bianchi , Noa Biran , Malin Hultcrantz , Joshua Ryan Richter , Ravi Vij , Jing Christine Ye , Jeffrey A. Zonder , Lauren DiLello , Jen Yesil , Hearn J. Cho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03732703
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8055)
DOI
10.1200/JCO.2022.40.16_suppl.8055
Abstract #
8055
Poster Bd #
478
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
The myeloma-developing regimens using genomics (MyDRUG) master protocol.
First Author: Daniel Auclair
Poster
2024 ASCO Annual Meeting
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.
First Author: Alexandre Harle
Poster
2023 ASCO Annual Meeting
Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers.
First Author: Ji Son
Poster
2019 ASCO Annual Meeting
Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.
First Author: Tyler J. Moss